Alumis Inc. Director Increases Stock Holdings, Current Price at $8.54

Summary

Alumis Inc. (NASDAQ: ALMS) director Alan Colowick purchased 16,104 shares at $6.97 per share, totaling $112,244.88 on April 1st. This increases his holdings to 16,104 shares. The stock currently trades at $8.54, with a price range over the last year from $3.18 to $13.53. Analysts maintain a ‘buy’ rating with a target price averaging $26.00. Institutional investment in Alumis has also seen a significant increase recently.Market Beat

Impact Analysis

The event is at the company level, specifically affecting Alumis Inc. The director’s purchase indicates confidence in the company’s prospects, potentially signaling positive insider sentiment. The stock’s recent price of $8.54 is below the analysts’ target average of $26.00, suggesting potential upside. Furthermore, institutional investment has increased, underscoring growing market confidence. This purchase follows a collaboration announcement with Kaken Pharmaceuticals and positive ratings from analysts, reinforcing the company’s strategic position Benzinga+ 2. Despite not being highlighted by top analysts as a prime investment opportunity Market Beat, the insider buy could influence investor sentiment positively, presenting a possible buy opportunity given the current market price and favorable analyst ratings.